Dose effect of Actisaf Sc 47 yeast probiotic () supplementation on production, reproduction, and negative energy balance in early lactation dairy cows.

The study evaluated the dose effect of dietary supplementation with yeast probiotic (CNCM I-4407, 10 CFU/g, Actisaf Sc 47; Phileo by Lesaffre, France) on production, energy metabolism, and reproduction in lactating dairy cows. About 117 multiparous Holstein cows from 3 to 60 d in milk held in a barn with an automatic milking system were enrolled in a randomized complete block design and blocked according to calving day, parity, and previous milk yield. The cows were assigned to a basal diet (15% CP, 22% starch) plus either 5 g (Y5 group,  = 39), 10 g (Y10 group,  = 39), or 0 g (CON,  = 39) of yeast probiotic, presented on top of concentrate fed in the robot.

Does micro-granulated yeast probiotic () supplementation in milk replacer affect health, growth, feed efficiency and economic gain of calves?

The goal of calf feeding systems is to provide calves with optimum nutrition to promote growth, health, and future milk production and to reduce antibiotic use which leads to a need for alternatives that reduce illness and promote growth in dairy calves. We hypothesized that feeding live yeast would improve gastrointestinal health and growth performance of calves. The aim of this study was then to evaluate the effects of supplementing a yeast probiotic (CNCM I-4407, 10 CFU/g, Actisaf® Sc47 powder; Phileo by Lesaffre, France) in milk replacers (MR), on health and growth of pre-weaned calves.

Dietary Supplementation of a Live Yeast Product on Dairy Sheep Milk Performance, Oxidative and Immune Status in Peripartum Period.

This study evaluated the dietary administration of live yeast on milk performance and composition, oxidative status of both blood plasma and milk, and gene expression related to the immune system of lactating ewes during the peripartum period. Chios ewes were fed either a basal diet (BD) (Control, = 51) or the BD supplemented with 2 g of a live yeast product/animal (ActiSaf, = 53) from 6 weeks prepartum to 6 weeks postpartum. Fatty acid profile, oxidative, and immune status were assessed in eight ewes per treatment at 3 and 6 weeks postpartum.

A trial of imaging selection and endovascular treatment for ischemic stroke.

Background: Whether brain imaging can identify patients who are most likely to benefit from therapies for acute ischemic stroke and whether endovascular thrombectomy improves clinical outcomes in such patients remains unclear.

Methods: In this study, we randomly assigned patients within 8 hours after the onset of large-vessel, anterior-circulation strokes to undergo mechanical embolectomy (Merci Retriever or Penumbra System) or receive standard care. All patients underwent pretreatment computed tomography or magnetic resonance imaging of the brain.

Design and rationale of the Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy (MR RESCUE) Trial.

Rationale: Multimodal imaging has the potential to identify acute ischaemic stroke patients most likely to benefit from late recanalization therapies.

Aims: The general aim of the Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy Trial is to investigate whether multimodal imaging can identify patients who will benefit substantially from mechanical embolectomy for the treatment of acute ischaemic stroke up to eight-hours from symptom onset.

Design: Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy is a randomized, controlled, blinded-outcome clinical trial.